Aurora Cannabis Names Faris El Refaie EVP, Global Commercial
Canadian MSO creates new C-suite role, taps 25-year biopharma veteran to lead worldwide sales strategy.
Distinguished mature businessman in a suit standing confidently in a modern office.
New C-Suite Role Signals Commercial Consolidation
Aurora created the EVP, global commercial position to unify its medical cannabis and adult-use sales under one leader. It's a structural shift. The company's pushing to scale distribution in Europe and Australia. Wednesday's announcement said the appointment is effective immediately.
El Refaie will report directly to CEO Miguel Martin. He'll consolidate oversight of Aurora's branded product portfolio—including medical brands MedReleaf and CanniMed—and its international wholesale channels.
El Refaie's Track Record in Pharma Distribution
El Refaie spent 25 years in biopharmaceutical sales and commercial strategy, most recently leading market-access initiatives for specialty-drug portfolios in regulated international markets. His background includes roles at mid-cap pharma companies navigating reimbursement frameworks in the EU and APAC regions.
Aurora didn't disclose his most recent employer or specific prior titles. What the company did emphasize: his experience securing formulary listings and building distributor networks in jurisdictions with centralized procurement systems. Those skill sets apply directly to medical cannabis channels in Germany, the UK, and Australia.
Aurora's International Exposure and Revenue Mix
Aurora derived 23% of Q4 2025 revenue from international medical sales, up from 18% a year earlier, according to its latest 10-K filing. The company holds EU-GMP certifications at two facilities and supplies medical cannabis to 20 countries.
The hire comes as Aurora faces margin pressure in the Canadian adult-use market, where per-gram wholesale prices fell 11% year-over-year in calendar 2025. International medical channels carry higher gross margins—42% versus 28% domestically—but they require navigating complex tender processes and reimbursement negotiations.
Next catalyst? Aurora reports fiscal Q1 2026 earnings on November 14. Investors will watch for commentary on European volume growth and whether the commercial reorganization translates to faster market-share gains in Germany, where Aurora ranks fourth by prescription volume.
Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Business
French Quarter Opens First Cannabis Dispensary in New Orleans History
A medical marijuana pharmacy has opened in the historic French Quarter, marking a retail milestone for Louisiana's cannabis program.
Massachusetts Cannabis Sales Surpass $10 Billion Since 2018 Launch
The state's adult-use market crossed the cumulative revenue threshold in September 2026, eight years after the first dispensaries opened.
South Africa eyes Canada's global cannabis export crown
Lower costs and EU-GMP capacity position South Africa as a serious threat to Canada's medical export dominance.
More from the newsroom
Missouri sets 0.4mg THC threshold, pulls hemp products into adult-use market Nov. 12
Anything above 0.4 milligrams of THC per container becomes marijuana, sellable only through licensed dispensaries.
Netherlands Cannabis Policies Show Structural Gaps Despite Coffeeshop Model
Policy analysts highlight enforcement inconsistencies and supply-chain ambiguities in Dutch cannabis framework.
Vermont Lieutenant Governor Accused of Violating State Cannabis Laws
State official faces allegations of breaking Vermont's cannabis regulations, raising questions about enforcement and political accountability.